Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$0.66
+5.5%		$0.68
$0.49
▼
$2.25
$61.37M3.48168,642 shs64,479 shs
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.82
+6.4%		$1.53
$1.28
▼
$9.50
$61.21M1.778,591 shs66,410 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$5.41
+3.4%		$6.65
$0.72
▼
$20.32
$52.10M1.092.04 million shs29,349 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$5.50
+15.7%		$8.63
$4.21
▼
$23.25
$136.22M0.3811,228 shs60,195 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
+5.59%+12.48%-8.08%-34.64%-69.64%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+4.27%+11.76%+14.77%+18.75%-64.74%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
+2.35%-2.24%-30.27%-66.15%+144.39%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-19.01%-39.28%-43.46%-54.30%-62.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$0.66
+5.5%		$0.68
$0.49
▼
$2.25
$61.37M3.48168,642 shs64,479 shs
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.82
+6.4%		$1.53
$1.28
▼
$9.50
$61.21M1.778,591 shs66,410 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$5.41
+3.4%		$6.65
$0.72
▼
$20.32
$52.10M1.092.04 million shs29,349 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$5.50
+15.7%		$8.63
$4.21
▼
$23.25
$136.22M0.3811,228 shs60,195 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
+5.59%+12.48%-8.08%-34.64%-69.64%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+4.27%+11.76%+14.77%+18.75%-64.74%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
+2.35%-2.24%-30.27%-66.15%+144.39%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-19.01%-39.28%-43.46%-54.30%-62.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
2.33
Hold$6.00809.09% Upside
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
2.00
Hold$12.00559.34% Upside
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.67
Moderate Buy$5.00-7.58% Downside
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.00
Hold$22.50309.46% Upside

Current Analyst Ratings Breakdown

Latest LEXX, CTOR, EDSA, and DWTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/24/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/24/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/14/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/13/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/30/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/29/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/25/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/24/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/16/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/19/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/A$0.54 per shareN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/A$2.33 per shareN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.45 per shareN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$710K191.86N/AN/A$0.13 per share42.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$34.26M-$10.60N/AN/AN/AN/A-108.57%-30.28%8/12/2026 (Estimated)
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$11.90M-$0.34N/AN/AN/AN/A-174.93%-143.89%N/A

Latest LEXX, CTOR, EDSA, and DWTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q3 2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.04N/AN/AN/A$5.83 millionN/A
8/14/2026N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.44N/AN/AN/AN/AN/A
8/12/2026Q2 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.13N/AN/AN/AN/AN/A
7/13/2026Q3 2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.90-$1.20-$0.30-$0.08$0.05 millionN/A
5/15/2026Q2 2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million
5/14/2026Q1 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.22-$0.15+$0.07-$0.15N/AN/A
5/14/2026Q2 2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.24-$0.49-$0.25-$0.49$0.05 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.11
0.50
0.12
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/A
5.86
5.86
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
4.76
4.76
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
10.61
10.61

Institutional Ownership

CompanyInstitutional Ownership
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
70.52%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
9.05%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%

Insider Ownership

CompanyInsider Ownership
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
9.80%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
0.30%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
24.40%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
8.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/A92.98 million83.87 millionN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
533.63 million33.53 millionN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
209.63 million7.28 millionNot Optionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
724.79 million22.71 millionNot Optionable

Recent News About These Companies

Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026  |  thenewswire.comT
Research Analysts Set Expectations for LEXX FY2026 Earnings
July 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30919421
Lexaria Updates Business Development
July 6, 2026  |  accessnewswire.comA
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
June 25, 2026  |  thenewswire.comT
Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule
June 23, 2026  |  thenewswire.comT
Lexaria Bioscience Corp.: GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68793083-lexaria-bioscience-corp-glp-1-arms-race-intensifies-as-the-addressable-markets-continue-to-expand-200.htm
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
June 17, 2026  |  thenewswire.comT
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 17, 2026  |  accessnewswire.comA
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 9, 2026  |  accessnewswire.comA
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
June 9, 2026  |  thenewswire.comT
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 3, 2026  |  accessnewswire.comA
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program
June 3, 2026  |  thenewswire.comT
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026  |  accessnewswire.comA
Lexaria Bioscience Corp.: Lexaria Bioscience Releases Second Episode of Investor Video Series
May 7, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68427480-lexaria-bioscience-corp-lexaria-bioscience-releases-second-episode-of-investor-video-series-200.htm
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 7, 2026  |  thenewswire.comT
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 1, 2026  |  accessnewswire.comA
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026  |  accessnewswire.comA
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026  |  thenewswire.comT
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026  |  accessnewswire.comA
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026  |  thenewswire.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A semiconductor wafer with the SK hynix logo displayed inside a manufacturing fabrication facility.
SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
By Thomas Hughes | July 7, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
Illustration of a quantum computing chandelier with the IQM logo, surrounded by cryogenic quantum computer units in a lab.
IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave
By Nathan Reiff | July 10, 2026
Semiconductor wafers and chips on a lab table beside server racks, with a declining stock price candlestick chart overlay.
The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
By Jeffrey Neal Johnson | July 7, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Citius Oncology stock logo

Citius Oncology NASDAQ:CTOR

$0.66 +0.03 (+5.53%)
As of 03:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Dogwood Therapeutics stock logo

Dogwood Therapeutics NASDAQ:DWTX

$1.82 +0.11 (+6.43%)
As of 03:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$5.41 +0.18 (+3.44%)
As of 03:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$5.50 +0.75 (+15.68%)
As of 03:44 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas